Recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination
PURPOSE: To report recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination in two patients with quiescent disease activity for more than a year.
METHODS: Retrospective observational case reports.
RESULTS: Two patients (one female and one male) under follow-up for posterior uveitis having stable course with absence of ocular inflammation for more than a year presented with recurrence of choroiditis lesions 2-6 weeks following anti-SARS-CoV-2 vaccination. Both the patients were managed with intravitreal dexamethasone implant (Ozurdex®, Allergan, Inc., Irvine, CA, USA) and showed resolution of choroiditis lesions upon follow-up.
CONCLUSIONS: Acute onset recurrence of inflammation, in absence of any change in health status or treatment suggests the potential role of vaccination being the trigger of this reactivation. Given large-scale vaccination against novel coronavirus- SARS-CoV-2, careful vigilance is warranted to pick up the disease recurrence in patients with posterior uveitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
European journal of ophthalmology - 33(2023), 3 vom: 09. Mai, Seite NP118-NP121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arora, Atul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 01.05.2023 Date Revised 01.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/11206721221088439 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338374396 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338374396 | ||
| 003 | DE-627 | ||
| 005 | 20231226000528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/11206721221088439 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338374396 | ||
| 035 | |a (NLM)35306917 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arora, Atul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2023 | ||
| 500 | |a Date Revised 01.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To report recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination in two patients with quiescent disease activity for more than a year | ||
| 520 | |a METHODS: Retrospective observational case reports | ||
| 520 | |a RESULTS: Two patients (one female and one male) under follow-up for posterior uveitis having stable course with absence of ocular inflammation for more than a year presented with recurrence of choroiditis lesions 2-6 weeks following anti-SARS-CoV-2 vaccination. Both the patients were managed with intravitreal dexamethasone implant (Ozurdex®, Allergan, Inc., Irvine, CA, USA) and showed resolution of choroiditis lesions upon follow-up | ||
| 520 | |a CONCLUSIONS: Acute onset recurrence of inflammation, in absence of any change in health status or treatment suggests the potential role of vaccination being the trigger of this reactivation. Given large-scale vaccination against novel coronavirus- SARS-CoV-2, careful vigilance is warranted to pick up the disease recurrence in patients with posterior uveitis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IMMUNOLOGY | |
| 650 | 4 | |a RETINA | |
| 650 | 4 | |a UVEA | |
| 650 | 4 | |a UVEITIS | |
| 650 | 4 | |a choroidal/retinal inflammation | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a posterior uveitis | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Handa, Sabia |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Simar Rajan |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Aman |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Reema |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Rupesh |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Vishali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of ophthalmology |d 1996 |g 33(2023), 3 vom: 09. Mai, Seite NP118-NP121 |w (DE-627)NLM012606944 |x 1724-6016 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:3 |g day:09 |g month:05 |g pages:NP118-NP121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/11206721221088439 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 3 |b 09 |c 05 |h NP118-NP121 | ||